|
|
|
|
|
Bendroflumethiazide
drug data and news
Bendroflumethiazide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Bendroflumethiazide | ||
| Brand Names/Synonyms | Aprinox; BHFT; BL H368; Bendrofluazide; Bendroflumethazide; Bendroflumethiazide; Bendroflumethiazide [Inn]; Bendroflumethiazidum [Inn-Latin]; Bendroflumetiazida [Inn-Spanish]; Bendroflumetiazide [Dcit]; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzy-Rodiuran; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bhft; Bristuric; Bristuron; CHEMBANK917; Centyl; Corzide; FT 8; FT 81; Flumersil; Flumesil; HSDB 3293; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturetin-2.5; Naturine; Neo-Naclex; Neo-Rontyl; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rautrax N; Rauzide; Relan Beta; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea | ||
| Indication | For the treatment of high blood pressure and management of edema | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Bendroflumethiazide, a thiazide diuretic, removes excess water from the body by increasing how often you urinate (pass water) and also widens the blood vessels which helps to reduce blood pressure. It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. | ||
| Mechanism Of Action | As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. | ||
| Bendroflumethiazide News (When available) |
King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Diuretics, Thiazide; Antihypertensive Agents; ATC:C03AA01 | ||
| Absorption | Absorbed relatively rapidly after oral administration | ||
| Interactions |
Interactions for Bendroflumethiazide: May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly; take the diuretic at least 1 hour before or 4 hours after cholestyramine or colestipol), digitalis glycosides (use with thiazide diuretics may cause high blood levels of digoxin, which may increase the chance of side effects), and lithium (use with thiazide diuretics may cause high blood levels of lithium, which may increase the chance of side effects). | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3-benzyl-5,5-dioxo-9-(trifluoromethyl)-5$l^{6}-thia-2,4-diazabicyclo[4.4.0]deca-7,9,11-triene-8-sulfonamide | ||
| Chemical Formula | C15H14F3N3O4S2 | ||
| Molecular Weight | 421.417 g/mol | ||
| Smiles String | C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2 | ||
| Melting Point | 221-223 °C | ||
| Water Solubility | 108 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 2.085 | ||
| Isoelectric Point | 8.5 | ||
| Biotransformation | Not Available | ||
| Half Life | 8.5 hours | ||
| Protein Binding [%] | 96% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Bendroflumethiazide.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00666 | ||
| CAS Registry Number | 73-48-3 | ||
| KEGG Compound ID | C07758 | ||
| PubChem ID | SID:9960 | ||
| PharmGKB ID | PA448563 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 29343 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |